Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients

Immunotherapy targeting programmed death receptor 1 and programmed death ligand 1 (PD-L1) has shown impressive antitumor efficacy in several solid cancers, including advanced hepatocellular carcinoma (HCC). Since response rates of various cancers to such immunotherapy appear to correlate with PD-L1...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Jian-Hong, Luo, Cheng-Piao, Zhang, Chun-Yan, Li, Le-Qun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221808/
https://www.ncbi.nlm.nih.gov/pubmed/28116284
http://dx.doi.org/10.2147/JHC.S122807
_version_ 1782492884640989184
author Zhong, Jian-Hong
Luo, Cheng-Piao
Zhang, Chun-Yan
Li, Le-Qun
author_facet Zhong, Jian-Hong
Luo, Cheng-Piao
Zhang, Chun-Yan
Li, Le-Qun
author_sort Zhong, Jian-Hong
collection PubMed
description Immunotherapy targeting programmed death receptor 1 and programmed death ligand 1 (PD-L1) has shown impressive antitumor efficacy in several solid cancers, including advanced hepatocellular carcinoma (HCC). Since response rates of various cancers to such immunotherapy appear to correlate with PD-L1 expression levels, several studies have examined whether PD-L1 expression correlates with HCC pathology and patient prognosis. In this paper, we analyzed the strength and limitations of a recent meta-analysis of associations of PD-L1 with HCC characteristics and patient prognosis.
format Online
Article
Text
id pubmed-5221808
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-52218082017-01-23 Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients Zhong, Jian-Hong Luo, Cheng-Piao Zhang, Chun-Yan Li, Le-Qun J Hepatocell Carcinoma Commentary Immunotherapy targeting programmed death receptor 1 and programmed death ligand 1 (PD-L1) has shown impressive antitumor efficacy in several solid cancers, including advanced hepatocellular carcinoma (HCC). Since response rates of various cancers to such immunotherapy appear to correlate with PD-L1 expression levels, several studies have examined whether PD-L1 expression correlates with HCC pathology and patient prognosis. In this paper, we analyzed the strength and limitations of a recent meta-analysis of associations of PD-L1 with HCC characteristics and patient prognosis. Dove Medical Press 2016-12-30 /pmc/articles/PMC5221808/ /pubmed/28116284 http://dx.doi.org/10.2147/JHC.S122807 Text en © 2017 Zhong et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Commentary
Zhong, Jian-Hong
Luo, Cheng-Piao
Zhang, Chun-Yan
Li, Le-Qun
Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients
title Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients
title_full Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients
title_fullStr Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients
title_full_unstemmed Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients
title_short Strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients
title_sort strengthening the case that elevated levels of programmed death ligand 1 predict poor prognosis in hepatocellular carcinoma patients
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5221808/
https://www.ncbi.nlm.nih.gov/pubmed/28116284
http://dx.doi.org/10.2147/JHC.S122807
work_keys_str_mv AT zhongjianhong strengtheningthecasethatelevatedlevelsofprogrammeddeathligand1predictpoorprognosisinhepatocellularcarcinomapatients
AT luochengpiao strengtheningthecasethatelevatedlevelsofprogrammeddeathligand1predictpoorprognosisinhepatocellularcarcinomapatients
AT zhangchunyan strengtheningthecasethatelevatedlevelsofprogrammeddeathligand1predictpoorprognosisinhepatocellularcarcinomapatients
AT lilequn strengtheningthecasethatelevatedlevelsofprogrammeddeathligand1predictpoorprognosisinhepatocellularcarcinomapatients

Ejemplares similares